COVID-19 symptom duration predicts immunoglobulin G seropositivity

Bratisl Lek Listy. 2021;122(12):861-865. doi: 10.4149/BLL_2021_139.

Abstract

Objectives: The study focused on the relationship between routine clinical characteristics and anti-SARS-CoV-2 specific antibodies in a pilot sample of healthcare workers (HCWs) having suffered COVID-19. The aim was to investigate the existence of readily available predictors of antibodies against COVID-19.

Methods: As part of the recognition of COVID-19 as an occupational disease in 152 HCWs with the mean age of 43.2 years, personal, anthropometric and anamnestic data related to the disease as well as anti-spike immunoglobulin (Ig) levels were obtained. Through descriptive statistics, correlation and regression analyses, relationships of all variables and Ig levels, especially seropositivity of IgG, were investigated.

Results: The mean interval between the symptom onset and the determination of antibodies was 58 days. IgG seropositivity and IgM seropositivity were noted in 82 % and 49 % of HCWs, respectively. Symptom duration was the only statistically significant predictor of IgG seropositivity. With each day of symptom duration, the probability of IgG seropositivity increased from 1.078 to 1.092 times (p < 0.05). If symptoms lasted longer than 17 days, a majority (almost 80 %) of the subjects demonstrated seropositivity in the following months. CONCLUSION: The presence of IgG immunity may be assumed from symptom duration. Such easy recognizing of seropositive patients may be a useful tool, e.g. in vaccination strategies (Tab. 3, Fig. 1, Ref. 28).

Keywords: COVID-19; SARS-CoV-2; antibody; immunoglobulin predictor.; seropositivity.

MeSH terms

  • Adult
  • Antibodies, Viral
  • COVID-19*
  • Health Personnel
  • Humans
  • Immunoglobulin G*
  • SARS-CoV-2

Substances

  • Antibodies, Viral
  • Immunoglobulin G